Nycomed's FY 2007 EBITDA jumps 31%

In 2007, Danish drugmaker Nycomed increased adjusted earnings before interest taxes, depreciation and amortization 31% on the year before to 1.22 billion euros ($1.87 billion). The performance was accompanied by major advancements in the US out-licensing efforts that materialized in early 2008, the firm noted.

"In the fourth quarter of 2007, we finalized a couple of agreements that are proof of our growth strategy, among others, the acquisition of Bradley Pharmaceuticals was successfully closed in early 2008, as were agreements with Sepracor and Baxter International in the USA. Our markets in Latin America and Russia/Commonwealth of Independent States as well as in southern and eastern Europe continued to grow at very satisfactory rates. And our substantial increase in adjusted EBITDA demonstrates our ability to focus on high-efficiency performance," said company chief executive Hakan Bjorklund.